trending Market Intelligence /marketintelligence/en/news-insights/trending/05AbhiF2ViO6mlHBFjSH1Q2 content esgSubNav
In This List

Clearside Biomedical seeks US FDA approval for eye drug

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Clearside Biomedical seeks US FDA approval for eye drug

Clearside Biomedical Inc. submitted a new drug application with the U.S. Food and Drug Administration seeking approval for its eye drug Xipere.

The Alpharetta, Ga.-based drugmaker is seeking the regulator's nod for Xipere as a treatment for macular edema — a build-up of fluid in a part of the eye — associated with uveitis, or the inflammation of the eye's middle layer.

Uveitis affects about 350,000 patients in the U.S. and over a million globally, Clearside said in a news release.